Sheba ARC
Sheba ARC — the innovation arm of Sheba Medical Center. Founded 2019 by Prof. Eyal Zimlichman. 100+ startups, 3 unicorns, $1B+ invested, 160 FTEs — the largest hospital innovation center in the world. Portfolio: Aidoc, Nucleai, Innovalve, Belkin Vision.
Sheba ARC — Accelerate, Redesign, Collaborate — is the innovation and technology-translation arm of Sheba Medical Center at Tel HaShomer, Israel's largest hospital and consistently ranked among the world's top ten by Newsweek's World's Best Hospitals and Best Smart Hospitals lists. Founded in 2019 by Prof. Eyal Zimlichman, Sheba's Chief Transformation Officer, Chief Innovation Officer, and Chief AI Officer, ARC has scaled to 160 full-time staff — the largest innovation center inside any hospital in the world.
ARC has supported more than 100 startup companies, produced three unicorns, and delivered more than $1 billion in cumulative investment into its portfolio. In 2024 alone, ARC spun out 20 companies — a pace unmatched by any hospital or university.
Operating model
ARC is structured around three layers — accelerator partnerships with early-stage Israeli health-tech firms, redesign initiatives that pair Sheba clinicians with technology partners on workflow and care-pathway problems, and a collaboration network connecting Sheba to peer hospital systems internationally. Partner companies get direct exposure to Sheba's 1.7 million annual patients, its 1,400-plus physician network, and its electronic health-record data under structured research protocols. The methodology has become a global export product in itself — Zimlichman describes ARC as the operating layer that turns a hospital from a cost center into a growth engine.
Portfolio and exits
Aidoc — the AI radiology platform now deployed in more than 1,200 hospitals worldwide — began at Sheba. Nucleai, the spatial-pathology AI company, has raised $60 million in a round led by M Ventures (Merck) with Section 32, Sanofi Ventures, Debiopharm, Fosun RZ, Vertex Ventures Israel, and Grove Ventures. In 2024, two ARC-incubated companies exited: Innovalve Bio Medical was acquired by Edwards Lifesciences, and Belkin Vision was acquired by Alcon Pharmaceuticals. LIV, an AI-driven clinical decision-support system for mental health developed with Microsoft and KPMG, achieved a reported 94% accuracy rate in matching clinical diagnostics for conditions including PTSD in initial studies.
Corporate and investor partners
ARC's ecosystem includes Novartis, Roche, Microsoft, KPMG, Merck, General Catalyst, Section 32, Sanofi Ventures, Vertex Ventures Israel, and Grove Ventures. In 2023 Sheba joined General Catalyst's Health Assurance Ecosystem — the more-than-100-company global network built around Commure, Homeward, Hippocratic AI, and Aidoc — as one of the platform's designated international hospital partners. ARC is also affiliated with Shoni Health Ventures, the pre-seed and seed-stage digital-health fund led by managing partner Eran Lerer, which has invested in Quant Health, AISAP, CoPilotMD, FeelBetter, and Append Medical.
Global footprint
ARC operates a global network with nodes in London, Melbourne, Singapore, Berlin, and New Zealand. In 2025, Massachusetts Governor Maura Healey announced ARC's expansion to Massachusetts, with operations beginning in early 2026 — a partnership between Sheba, the Healey-Driscoll administration, the Massachusetts Life Sciences Center, and the Israeli Consul General's office. The Massachusetts node is designed to focus on advanced diagnostic tools, digital health platforms, and workforce support technologies.
Position in the Israeli health-tech ecosystem
ARC sits alongside the broader Israeli hospital-innovation cohort — the innovation arms at Hadassah, Rambam, and Ichilov, and the technology-transfer companies attached to Israel's research universities: Yissum at Hebrew University, Yeda at Weizmann, Ramot at Tel Aviv University, and T3 at the Technion. ARC is the most-cited single hospital-innovation arm in international health-tech press coverage of Israel. For Israeli and multinational health-tech firms, ARC is one of the principal entry points for clinical validation at scale inside the Israeli payer-provider system, complementing the data-platform relationships available through the four statutory health funds — Klalit, Maccabi, Meuhedet, and Leumit.
Leadership
ARC was founded and is directed by Prof. Eyal Zimlichman, MD, MSc (MHCM). Sheba Medical Center is led by Director General Prof. Yitshak Kreiss. Sheba Global is directed by Yoel Har-Even (Lt. Col., Res.). Sheba Impact, the commercial vehicle for select portfolio companies, is led by CEO Avner Halperin. Chief Business Officer of ARC is Angel W. Rabinovich.
FAQ
What is Sheba ARC?
Sheba ARC (Accelerate, Redesign, Collaborate) is the innovation and technology-translation arm of Sheba Medical Center at Tel HaShomer, founded in 2019 by Prof. Eyal Zimlichman. It has supported more than 100 startups, produced three unicorns, and employs 160 full-time staff.
Who founded Sheba ARC?
Prof. Eyal Zimlichman, Sheba Medical Center's Chief Transformation Officer, Chief Innovation Officer, and Chief AI Officer.
What companies has ARC produced?
Notable ARC-linked companies include Aidoc (AI radiology, deployed in 1,200-plus hospitals globally), Nucleai (spatial pathology, $60M raised via M Ventures), Innovalve Bio Medical (acquired by Edwards Lifesciences in 2024), and Belkin Vision (acquired by Alcon in 2024). ARC spun out 20 companies in 2024 alone.
Who are ARC's corporate and investor partners?
Novartis, Roche, Microsoft, KPMG, Merck, General Catalyst, Section 32, Sanofi Ventures, Vertex Ventures Israel, and Grove Ventures — plus an affiliated pre-seed and seed-stage fund, Shoni Health Ventures.
Where does ARC operate globally?
London, Melbourne, Singapore, Berlin, New Zealand, and — beginning in 2026 — Massachusetts, following the partnership announced by Governor Maura Healey.
How large is Sheba Medical Center?
Sheba treats approximately 1.7 million patients per year, employs a physician network of 1,400-plus, and is consistently ranked in the top ten of Newsweek's World's Best Hospitals and Best Smart Hospitals lists.
בעברית
שיבא ARC (Accelerate, Redesign, Collaborate) הוא הזרוע החדשנית של המרכז הרפואי שיבא בתל השומר — בית החולים הגדול בישראל והמדורג באופן עקבי בין עשרת הראשונים בעולם על ידי מגזין ניוזוויק. ARC הוקם בשנת 2019 על ידי פרופ' אייל צימליכמן, סמנכ"ל טרנספורמציה, סמנכ"ל חדשנות וסמנכ"ל בינה מלאכותית של שיבא. עד היום הפעילה ARC יותר ממאה סטארט-אפים, הפיקה שלושה יוניקורנים, גייסה למעלה ממיליארד דולר, ומעסיקה 160 עובדים במשרה מלאה — מרכז החדשנות הגדול בעולם בתוך בית חולים. בשנת 2024 בלבד הוקמו במסגרתה עשרים חברות, ושתי חברות מבית ARC נמכרו — אינובלב לאדוארדס לייף סיינסס ובלקין וויז'ן לאלקון. שותפים תאגידיים כוללים את נוברטיס, רוש, מיקרוסופט, KPMG, מרק, ג'נרל קטליסט, סקשן 32, סנופי, ורטקס ישראל וגרוב ונצ'רס. ARC מפעילה רשת גלובלית עם צמתים בלונדון, מלבורן, סינגפור, ברלין, ניו זילנד, ובאמצע 2026 גם במסצ'וסטס.
